News
This combination has “the potential to become a new standard first-line treatment” for well-differentiated grade 1/2 gastroenteropancreatic neuroendocrine tumors with poor prognostic factors ...
Among patients with grade 1 (least aggressive) or grade 2 (more aggressive than grade 1) somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), the phase 3 COMPETE ...
There are 3 grades of neuroendocrine tumours (NETs) – grade 1, 2 and 3a: Grade 1 cancers grow slowly. They are low grade. Grade 2 grow at a moderate pace (between 1 and 3). ... European Neuroendocrine ...
Novel framework for response evaluation criteria in grade 1/2 neuroendocrine tumors (RECIN) following [177Lu]Lu-DOTATATE therapy: post-hoc analysis of the phase 2 LuCAP trial, European Journal of ...
A phase 3 trial establishes 177Lu-dotatate plus long-acting octreotide as a new first-line treatment for patients with high-grade gastroenteropancreatic neuroendocrine tumors.
A phase 1 trial combines immunotherapy and an oncolytic virus for high-grade neuroendocrine tumors, aiming to enroll 36 patients by 2030. The trial evaluates Opdivo, Yervoy, and Seneca Valley ...
This is a subset of neuroendocrine tumors that are low or intermediate grade. Because they start in hormone-producing cells, some lung neuroendocrine tumors can make hormone-like substances called ...
Appendix cancer is a rare but increasingly recognized malignancy, often discovered incidentally during surgery for presumed ...
SAN FRANCISCO -- Adding a radioligand to standard therapy almost tripled median progression-free survival (PFS) in untreated high-grade gastroenteropancreatic neuroendocrine tumors (GEP-NETs), a ...
A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive Cancer Center. The new trial will test the novel combination of ...
Exelixis (NASDAQ:EXEL) said on Wednesday that the U.S. FDA has approved cabozantinib for patients 12 years of age and older with pancreatic neuroendocrine tumors. The approval follows promising ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results